Click for best price
Blood Tumor Drugs Market Size, Share 2023
Blood Tumor, also known as hematological disease, is a type of cancer impacting bone marrow, blood, and lymph nodes. Different sorts of mature blood cells include white blood cells for immune protection, platelets for wound clotting, and red blood cells to carry oxygen. In the bone marrow, it originates from progenitor cells and hematopoietic stem. Hematologic malignancies initiate in these cells and are subcategorized as per the type of blood cell that is affected such as myeloid or myelogenous or and lymphocytic lymphoblastic. A malignancy in the lymphoid lineage involves B lymphocytes and T lymphocytes. Malignancy in the myeloid lineage involves precursor cells to white blood cells platelets and red blood cells.
This report aims to provide a comprehensive presentation of the global market for Blood Tumor Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Tumor Drugs. This report contains market size and forecasts of Blood Tumor Drugs in global, including the following market information:
Global Blood Tumor Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Blood Tumor Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Chemotherapy Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Blood Tumor Drugs include Bristol-Myers Squibb, Johnson & Johnson, AbbVie, Novartis, Roche, Amgen, Takeda, Pfizer and AstraZeneca, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We has surveyed the Blood Tumor Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Blood Tumor Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Blood Tumor Drugs Market Segment Percentages, by Type, 2022 (%)
Chemotherapy
Targeted Therapy
Immunotherapy
Other
Global Blood Tumor Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Blood Tumor Drugs Market Segment Percentages, by Application, 2022 (%)
Leukemia
Lymphoma
Multiple Myeloma
Others
Global Blood Tumor Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Blood Tumor Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Blood Tumor Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Blood Tumor Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol-Myers Squibb
Johnson & Johnson
AbbVie
Novartis
Roche
Amgen
Takeda
Pfizer
AstraZeneca
Gilead Sciences
Outline of Major Chapters:
Chapter 1: Introduces the definition of Blood Tumor Drugs, market overview.
Chapter 2: Global Blood Tumor Drugs market size in revenue.
Chapter 3: Detailed analysis of Blood Tumor Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Blood Tumor Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Blood Tumor Drugs Market, Global Outlook and Forecast 2023-2029 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
66 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Blood Tumor Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Blood Tumor Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Blood Tumor Drugs Overall Market Size
2.1 Global Blood Tumor Drugs Market Size: 2022 VS 2029
2.2 Global Blood Tumor Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Blood Tumor Drugs Players in Global Market
3.2 Top Global Blood Tumor Drugs Companies Ranked by Revenue
3.3 Global Blood Tumor Drugs Revenue by Companies
3.4 Top 3 and Top 5 Blood Tumor Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Blood Tumor Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Blood Tumor Drugs Players in Global Market
3.6.1 List of Global Tier 1 Blood Tumor Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Blood Tumor Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Blood Tumor Drugs Market Size Markets, 2022 & 2029
4.1.2 Chemotherapy
4.1.3 Targeted Therapy
4.1.4 Immunotherapy
4.1.5 Other
4.2 By Type - Global Blood Tumor Drugs Revenue & Forecasts
4.2.1 By Type - Global Blood Tumor Drugs Revenue, 2018-2023
4.2.2 By Type - Global Blood Tumor Drugs Revenue, 2024-2029
4.2.3 By Type - Global Blood Tumor Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Blood Tumor Drugs Market Size, 2022 & 2029
5.1.2 Leukemia
5.1.3 Lymphoma
5.1.4 Multiple Myeloma
5.1.5 Others
5.2 By Application - Global Blood Tumor Drugs Revenue & Forecasts
5.2.1 By Application - Global Blood Tumor Drugs Revenue, 2018-2023
5.2.2 By Application - Global Blood Tumor Drugs Revenue, 2024-2029
5.2.3 By Application - Global Blood Tumor Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Blood Tumor Drugs Market Size, 2022 & 2029
6.2 By Region - Global Blood Tumor Drugs Revenue & Forecasts
6.2.1 By Region - Global Blood Tumor Drugs Revenue, 2018-2023
6.2.2 By Region - Global Blood Tumor Drugs Revenue, 2024-2029
6.2.3 By Region - Global Blood Tumor Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Blood Tumor Drugs Revenue, 2018-2029
6.3.2 US Blood Tumor Drugs Market Size, 2018-2029
6.3.3 Canada Blood Tumor Drugs Market Size, 2018-2029
6.3.4 Mexico Blood Tumor Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Blood Tumor Drugs Revenue, 2018-2029
6.4.2 Germany Blood Tumor Drugs Market Size, 2018-2029
6.4.3 France Blood Tumor Drugs Market Size, 2018-2029
6.4.4 U.K. Blood Tumor Drugs Market Size, 2018-2029
6.4.5 Italy Blood Tumor Drugs Market Size, 2018-2029
6.4.6 Russia Blood Tumor Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Blood Tumor Drugs Market Size, 2018-2029
6.4.8 Benelux Blood Tumor Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Blood Tumor Drugs Revenue, 2018-2029
6.5.2 China Blood Tumor Drugs Market Size, 2018-2029
6.5.3 Japan Blood Tumor Drugs Market Size, 2018-2029
6.5.4 South Korea Blood Tumor Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Blood Tumor Drugs Market Size, 2018-2029
6.5.6 India Blood Tumor Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Blood Tumor Drugs Revenue, 2018-2029
6.6.2 Brazil Blood Tumor Drugs Market Size, 2018-2029
6.6.3 Argentina Blood Tumor Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Blood Tumor Drugs Revenue, 2018-2029
6.7.2 Turkey Blood Tumor Drugs Market Size, 2018-2029
6.7.3 Israel Blood Tumor Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Blood Tumor Drugs Market Size, 2018-2029
6.7.5 UAE Blood Tumor Drugs Market Size, 2018-2029
7 Blood Tumor Drugs Companies Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Company Summary
7.1.2 Bristol-Myers Squibb Business Overview
7.1.3 Bristol-Myers Squibb Blood Tumor Drugs Major Product Offerings
7.1.4 Bristol-Myers Squibb Blood Tumor Drugs Revenue in Global Market (2018-2023)
7.1.5 Bristol-Myers Squibb Key News & Latest Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Company Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Blood Tumor Drugs Major Product Offerings
7.2.4 Johnson & Johnson Blood Tumor Drugs Revenue in Global Market (2018-2023)
7.2.5 Johnson & Johnson Key News & Latest Developments
7.3 AbbVie
7.3.1 AbbVie Company Summary
7.3.2 AbbVie Business Overview
7.3.3 AbbVie Blood Tumor Drugs Major Product Offerings
7.3.4 AbbVie Blood Tumor Drugs Revenue in Global Market (2018-2023)
7.3.5 AbbVie Key News & Latest Developments
7.4 Novartis
7.4.1 Novartis Company Summary
7.4.2 Novartis Business Overview
7.4.3 Novartis Blood Tumor Drugs Major Product Offerings
7.4.4 Novartis Blood Tumor Drugs Revenue in Global Market (2018-2023)
7.4.5 Novartis Key News & Latest Developments
7.5 Roche
7.5.1 Roche Company Summary
7.5.2 Roche Business Overview
7.5.3 Roche Blood Tumor Drugs Major Product Offerings
7.5.4 Roche Blood Tumor Drugs Revenue in Global Market (2018-2023)
7.5.5 Roche Key News & Latest Developments
7.6 Amgen
7.6.1 Amgen Company Summary
7.6.2 Amgen Business Overview
7.6.3 Amgen Blood Tumor Drugs Major Product Offerings
7.6.4 Amgen Blood Tumor Drugs Revenue in Global Market (2018-2023)
7.6.5 Amgen Key News & Latest Developments
7.7 Takeda
7.7.1 Takeda Company Summary
7.7.2 Takeda Business Overview
7.7.3 Takeda Blood Tumor Drugs Major Product Offerings
7.7.4 Takeda Blood Tumor Drugs Revenue in Global Market (2018-2023)
7.7.5 Takeda Key News & Latest Developments
7.8 Pfizer
7.8.1 Pfizer Company Summary
7.8.2 Pfizer Business Overview
7.8.3 Pfizer Blood Tumor Drugs Major Product Offerings
7.8.4 Pfizer Blood Tumor Drugs Revenue in Global Market (2018-2023)
7.8.5 Pfizer Key News & Latest Developments
7.9 AstraZeneca
7.9.1 AstraZeneca Company Summary
7.9.2 AstraZeneca Business Overview
7.9.3 AstraZeneca Blood Tumor Drugs Major Product Offerings
7.9.4 AstraZeneca Blood Tumor Drugs Revenue in Global Market (2018-2023)
7.9.5 AstraZeneca Key News & Latest Developments
7.10 Gilead Sciences
7.10.1 Gilead Sciences Company Summary
7.10.2 Gilead Sciences Business Overview
7.10.3 Gilead Sciences Blood Tumor Drugs Major Product Offerings
7.10.4 Gilead Sciences Blood Tumor Drugs Revenue in Global Market (2018-2023)
7.10.5 Gilead Sciences Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Blood Tumor Drugs Market Opportunities & Trends in Global Market
Table 2. Blood Tumor Drugs Market Drivers in Global Market
Table 3. Blood Tumor Drugs Market Restraints in Global Market
Table 4. Key Players of Blood Tumor Drugs in Global Market
Table 5. Top Blood Tumor Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Blood Tumor Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Blood Tumor Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Blood Tumor Drugs Product Type
Table 9. List of Global Tier 1 Blood Tumor Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Blood Tumor Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Blood Tumor Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Blood Tumor Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Blood Tumor Drugs Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Blood Tumor Drugs Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Blood Tumor Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Blood Tumor Drugs Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Blood Tumor Drugs Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Blood Tumor Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Blood Tumor Drugs Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Blood Tumor Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Blood Tumor Drugs Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Blood Tumor Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Blood Tumor Drugs Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Blood Tumor Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Blood Tumor Drugs Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Blood Tumor Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Blood Tumor Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Blood Tumor Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Blood Tumor Drugs Revenue, (US$, Mn), 2024-2029
Table 30. Bristol-Myers Squibb Company Summary
Table 31. Bristol-Myers Squibb Blood Tumor Drugs Product Offerings
Table 32. Bristol-Myers Squibb Blood Tumor Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Bristol-Myers Squibb Key News & Latest Developments
Table 34. Johnson & Johnson Company Summary
Table 35. Johnson & Johnson Blood Tumor Drugs Product Offerings
Table 36. Johnson & Johnson Blood Tumor Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Johnson & Johnson Key News & Latest Developments
Table 38. AbbVie Company Summary
Table 39. AbbVie Blood Tumor Drugs Product Offerings
Table 40. AbbVie Blood Tumor Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. AbbVie Key News & Latest Developments
Table 42. Novartis Company Summary
Table 43. Novartis Blood Tumor Drugs Product Offerings
Table 44. Novartis Blood Tumor Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Novartis Key News & Latest Developments
Table 46. Roche Company Summary
Table 47. Roche Blood Tumor Drugs Product Offerings
Table 48. Roche Blood Tumor Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Roche Key News & Latest Developments
Table 50. Amgen Company Summary
Table 51. Amgen Blood Tumor Drugs Product Offerings
Table 52. Amgen Blood Tumor Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Amgen Key News & Latest Developments
Table 54. Takeda Company Summary
Table 55. Takeda Blood Tumor Drugs Product Offerings
Table 56. Takeda Blood Tumor Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Takeda Key News & Latest Developments
Table 58. Pfizer Company Summary
Table 59. Pfizer Blood Tumor Drugs Product Offerings
Table 60. Pfizer Blood Tumor Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. Pfizer Key News & Latest Developments
Table 62. AstraZeneca Company Summary
Table 63. AstraZeneca Blood Tumor Drugs Product Offerings
Table 64. AstraZeneca Blood Tumor Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. AstraZeneca Key News & Latest Developments
Table 66. Gilead Sciences Company Summary
Table 67. Gilead Sciences Blood Tumor Drugs Product Offerings
Table 68. Gilead Sciences Blood Tumor Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Gilead Sciences Key News & Latest Developments
List of Figures
Figure 1. Blood Tumor Drugs Segment by Type in 2022
Figure 2. Blood Tumor Drugs Segment by Application in 2022
Figure 3. Global Blood Tumor Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Blood Tumor Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Blood Tumor Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Blood Tumor Drugs Revenue in 2022
Figure 8. By Type - Global Blood Tumor Drugs Revenue Market Share, 2018-2029
Figure 9. By Application - Global Blood Tumor Drugs Revenue Market Share, 2018-2029
Figure 10. By Type - Global Blood Tumor Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Blood Tumor Drugs Revenue Market Share, 2018-2029
Figure 12. By Application - Global Blood Tumor Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Blood Tumor Drugs Revenue Market Share, 2018-2029
Figure 14. By Region - Global Blood Tumor Drugs Revenue Market Share, 2018-2029
Figure 15. By Country - North America Blood Tumor Drugs Revenue Market Share, 2018-2029
Figure 16. US Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Blood Tumor Drugs Revenue Market Share, 2018-2029
Figure 20. Germany Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 21. France Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Blood Tumor Drugs Revenue Market Share, 2018-2029
Figure 28. China Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. India Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Blood Tumor Drugs Revenue Market Share, 2018-2029
Figure 34. Brazil Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Blood Tumor Drugs Revenue Market Share, 2018-2029
Figure 37. Turkey Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Blood Tumor Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. Bristol-Myers Squibb Blood Tumor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Johnson & Johnson Blood Tumor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. AbbVie Blood Tumor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Novartis Blood Tumor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Roche Blood Tumor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Amgen Blood Tumor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Takeda Blood Tumor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Pfizer Blood Tumor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. AstraZeneca Blood Tumor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Gilead Sciences Blood Tumor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
